Abdera Therapeutics Email Format
Biotechnology ResearchCalifornia, United States11-50 Employees
Abdera Therapeutics is a clinical-stage biotechnology company focused on cancer therapies that use radiopharmaceuticals targeted to tumors. It pursues a modular technology platform engineered to direct radioactive isotopes to cancer cells while reducing exposure to healthy tissue. The company employs antibody engineering to develop tunable radiopharmaceuticals aimed at cancers with limited treatment options. Headquartered in South San Francisco, California, Abdera operates within the biotechnology research sector and advances its programs through clinical development. Its core customers are cancer patients with few effective options, and the company is positioned within the precision oncology landscape. In July 2025, Abdera appointed Dr. Rachael Brake as chief scientific officer, signaling leadership expansion.